63 completed, 46 unknown, 16 recruiting, 7 terminated. 147 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 147 | Completed 63, Unknown 46, Recruiting 16, Terminated 7, Not yet recruiting 6, Active not recruiting 5, Withdrawn 4 |
Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide - Preeclampsia, Preeclampsia Postpartum | Phase 4 | Recruiting | University of California, Irvine | 96 | 2026-10-26 | 2026-11-02 |
| Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 4 | Recruiting | The First Hospital of Jilin University | 26 | 2026-10-15 | 2026-11-02 |
| Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response Pomalidomide, Rituximab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 4 | Not yet recruiting | The First Hospital of Jilin University | 27 | 2026-09-01 | 2026-08-12 |
| Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy Cosibelimab, Prednisone, Sirolimus - Cutaneous Squamous Cell Carcinoma, Skin Cancer | Phase 4 | Recruiting | Dana-Farber Cancer Institute | 80 | 2026-04-23 | 2026-08-11 |
| ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial ZSDT regimen - Mantle Cell Lymphoma (MCL) | Phase 4 | Not yet recruiting | Zhengzhou University | 30 | 2025-12-31 | 2025-12-04 |
| Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma Orelabrutinib - Marginal Zone Lymphoma(MZL) | Phase 4 | Recruiting | Beijing Tongren Hospital | 88 | 2025-11-25 | 2026-01-21 |
| Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma Rituximab, Zanubrutinib - Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma | Phase 4 | Recruiting | The First Affiliated Hospital of Soochow University | 40 | 2025-11-01 | 2025-12-08 |
| Efficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL) chidamide+PD-1 inhibitor - Large B-Cell Lymphoma (LBCL), Lymphoma, Large B-Cell, Diffuse | Phase 4 | Recruiting | Shanghai Tongji Hospital, Tongji University School of Medicine | 20 | 2025-10-30 | 2026-11-13 |
| Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies Ceftazidime, Ciprofloxacin - Neutropenic Fever, Acute Lymphoblastic Leukemia | Phase 4 | Recruiting | Gadjah Mada University | 120 | 2025-06-01 | 2025-08-22 |
| Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma Glofitamab treatment - B Cell Lymphoma (BCL) | Phase 4 | Not yet recruiting | Zhengzhou University | 40 | 2025-05-30 | 2025-05-02 |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 279 | 2025-05-20 | 2026-03-02 |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib Pirtobrutinib - Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma | Phase 4 | Recruiting | Eli Lilly and Company | 787 | 2025-05-20 | 2026-03-02 |
| Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients Early receiving G-CSF group, Late receiving G-CSF group - Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor | Phase 4 | Not yet recruiting | Department of Medical Services Ministry of Public Health of Thailand | 126 | 2025-02-01 | 2025-01-28 |
| BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma Brentuximab Vedotin (Bv), Sintilimab, Tislelizumab - Hodgkin Lymphoma (Category) | Phase 4 | Not yet recruiting | Xiuhua Sun | 100 | 2024-12-31 | 2025-01-07 |
| A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis Efanesoctocog alfa - Haemophilia A (Moderate or Severe), Hemophilia, Classic | Phase 4 | Active not recruiting | Swedish Orphan Biovitrum | 37 | 2024-12-19 | 2026-04-30 |
| Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma Axicabtagene Ciloleucel - Lymphoma, B-Cell | Phase 4 | Recruiting | Zhengzhou University | 20 | 2024-09-30 | 2024-10-15 |
| A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India Brentuximab Vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 4 | Recruiting | Takeda | 124 | 2024-08-28 | 2026-02-23 |
| A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Pentaisomaltose - Malignant Lymphoma, Multiple Myeloma | Phase 4 | Unknown | Pharmacosmos A/S | 150 | 2024-04-30 | 2024-04-03 |
| Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy PCV20 - Lymphoma | Phase 4 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2023-10-06 | 2026-09-15 |
| A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma Relmacabtagene Autoleucel Injection - Relapsed or Refractory B-cell Lymphoma | Phase 4 | Not yet recruiting | Changhai Hospital | 13 | 2023-06-20 | 2023-06-15 |
Showing 20 of 147. Sign in to see all of them.
Lymphoma, Follicular (31) · Lymphoma, Non-Hodgkin (30) · Lymphoma, Large B-Cell, Diffuse (14) · Lymphoma, B-Cell (10) · Recurrence (10) · Hodgkin Disease (8) · Lymphoma, T-Cell, Cutaneous (8) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Mantle-Cell (6) · Mycosis Fungoides (6) · Burkitt Lymphoma (5) · Lymphoma, Extranodal NK-T-Cell (5)
Neoplasms by Histologic Type (146) · Neoplasms (145) · Hemic and Lymphatic Diseases (143) · Lymphatic Diseases (142) · Immune System Diseases (141) · Immunoproliferative Disorders (141) · Lymphoproliferative Disorders (141) · Lymphoma, Non-Hodgkin (82) · Hematologic Diseases (28) · Pathological Conditions, Signs and Symptoms (25) · Lymphoma, T-Cell (24) · Lymphoma, B-Cell (18) · Pathologic Processes (16) · Disease Attributes (15)
Rituximab (13) · Cyclophosphamide (12) · Doxorubicin (9) · Dexamethasone (8) · Etoposide (8) · Vincristine (7) · Granulocyte Colony-Stimulating Factor (6) · Prednisone (6) · Brentuximab Vedotin (5) · Cytarabine (5) · Ifosfamide (5) · Methotrexate (5) · pegylated granulocyte colony-stimulating factor (5) · Aprepitant (4) · Cisplatin (4)
Mingzhi Zhang (9) · Peking University (7) · Zhengzhou University (6) · Ruijin Hospital (5) · Eisai Inc. (4) · Shandong Provincial Hospital (4) · GlaxoSmithKline (3) · Takeda (3) · Biogen (2) · Children's Hospital of Michigan (2) · Chongqing University Cancer Hospital (2) · Depomed (2) · Eli Lilly and Company (2) · Hoffmann-La Roche (2) · Jun Zhu (2)
China (52) · United States (34) · Germany (12) · Italy (12) · Spain (11) · France (10) · Poland (9) · United Kingdom (9) · Australia (8) · Russia (8) · Sweden (7) · Czechia (6) · South Korea (6) · Taiwan (5) · Turkey (Türkiye) (5)
Jun Zhu (3) · Jun Zhu, MD (3) · Mingzhi Zhang, Pro,Dr (3) · Elyane Lombardy, M.D. (2) · A. Paz Coll, MD (1) · A. Salar, MD (1) · Adrian U Wiestner, M.D. (1)
PMID 32632956, PMID 23770157, PMID 11863096, PMID 14585365, PMID 14752084, PMID 15014526, PMID 15158091, PMID 15257960, PMID 15770833, PMID 16648042, PMID 17410187, PMID 18165618, PMID 18626005, PMID 19167677, PMID 19219604, PMID 20118030, PMID 20660832, PMID 21575927, PMID 21828124, PMID 21890336, PMID 21940824, PMID 22198540, PMID 22677206, PMID 23275102, PMID 23317527, PMID 23383989, PMID 23615461, PMID 23753028, PMID 23775967, PMID 23775972, PMID 23938061, PMID 24824768, PMID 25253770, PMID 25311218, PMID 25359988, PMID 25559471, PMID 25934708, PMID 26001791, PMID 26230956, PMID 26808342, PMID 27060152, PMID 27384676, PMID 27686365, PMID 27852260, PMID 28597542, PMID 28664750, PMID 29155058, PMID 29437609, PMID 29610030, PMID 29654631
2009 (2), 2016 (1), 2019 (1), P01CA128115 (1)